Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 30, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the Company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on March 29, 2007:
- Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("GSK Trust"), transferred 12,250 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- The Company was advised of these transactions on March 30, 2007.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, three directors—Dr. JP Garnier, Dr. M M Slaoui, and Mr. J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the impact of the 12,250 share transfer on the total outstanding share count and dilution metrics.
- Confirm the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 regarding vesting and exercise conditions.
- Review the full list of directors and their specific holdings within the GSK Trust to assess potential conflicts of interest or voting power.